Pexate 100 Mg Injection

What is Pexate 100 mg Injection

Pexate 100 mg is a chemotherapeutic agent used to treat Non-Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, and other advanced cancers in adult patients. Its primary ingredient is Pemetrexed (100 mg), a folate antimetabolite chemotherapy agent that disrupts folate-dependent metabolic processes essential for cell replication.

Miracalus Pharma Pvt Ltd is a renowned manufacturer of Pexate 100 mg. Healthcare professionals typically administer this medication intravenously in a clinical setting as part of a comprehensive cancer treatment protocol.

Side effects may include myelosuppression (low blood counts), fatigue, nausea, mucositis, and skin rash. Premedication with folic acid, vitamin B12, and dexamethasone helps reduce toxicity. Regular laboratory monitoring is essential to evaluate therapeutic response and detect potential complications during treatment.

The medicine may interact with several diseases, particularly those affecting bone marrow function. Myelosuppression is a significant concern, leading to decreased counts of red blood cells, white blood cells, and platelets, which increases the risk of infections and bleeding. Precautions are essential for patients with kidney disease, as Pemetrexed can worsen renal issues.

Additionally, caution is advised for those with heart conditions or who have undergone radiation therapy. Pemetrexed should not be used during pregnancy unless necessary, and breastfeeding should be avoided. Patients should also avoid live vaccines and inform their doctor about recent vaccinations or planned surgeries.

What are the benefits of Pexate 100 mg Injection

Pexate 100 Injection works by inhibiting multiple folate-dependent enzymes involved in purine and pyrimidine synthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This disruption prevents Cancer cells from synthesizing DNA and RNA, inhibiting cell division and tumor growth.

Pexate 100 offers several important therapeutic benefits:

• Effectively targets and inhibits rapidly dividing Cancer cells.
• Demonstrates efficacy against multiple Cancer types, particularly NSCLC and Mesothelioma.
• It can be used in combination with platinum compounds for enhanced anticancer activity.
• It may improve disease-related symptoms and quality of life.
• It can offer survival benefits in appropriate patient populations.

It is crucial to note that Pexate must be administered under close medical supervision with appropriate supportive care to manage potential side effects and optimize outcomes.

How to take Pexate 100 mg Injection

Pexate is a prescription medication that should be administered as per your oncologist's instructions. Here are the general guidelines:

• Pexate is given as an intravenous infusion over 10 minutes on the first day of each 21-day treatment cycle.
• A qualified healthcare expert must administer it in a clinical setting.
• Requires premedication with folic acid (350-1000 mcg daily) starting 7 days before treatment.
• Vitamin B12 (1000 mcg) Injection is needed the week before the first dose and every three cycles.
• Dexamethasone (4 mg twice daily) should be taken the day before, day of, and day after Pexate administration.

Strength and substitutes

The strength and substitutes available for Pexate Injection are:

View all substitutes

What are the side effects of Pexate 100 mg Injection

Pexate may cause side effects, which are generally manageable with appropriate supportive care. These include:

• Bone marrow suppression (low white blood cells, platelets, and red blood cells)
• Fatigue and weakness
• Nausea, vomiting, and diarrhea
• Mucositis (inflammation of mucous membranes)
• Skin rash and radiation recall dermatitis

These adverse effects typically require close monitoring and management by your healthcare team. Premedication protocols help reduce the frequency and severity of many side effects.

Safety Advice

Liver disease

Patients with liver issues may require dose adjustments. Close monitoring of liver function tests before each cycle is mandatory. Treatment should be delayed until liver function normalizes if significant abnormalities develop during therapy.

Kidney impairment

Dose adjustment is needed in people with renal impairment as the kidneys primarily eliminate Pexate. Patients with creatinine clearance <45 mL/min are generally not recommended to receive this medication. Regular monitoring of renal function before each treatment cycle is essential.

Pregnant and breastfeeding women

Pexate is contraindicated during pregnancy as it may cause fetal harm. Effective contraception is required during treatment and for 6 months after the last dose for both male and female patients. The medicine can pass into breast milk and could seriously harm a nursing infant. Breastfeeding must be discontinued during treatment and at least a week after the final dose.

Avoid

Concomitant use of nephrotoxic medications (NSAIDs, Aminoglycosides) should be avoided or used cautiously due to potential increased renal toxicity. Live vaccines should be avoided due to immunosuppression. Alcohol consumption may worsen side effects and should be limited. Patients should avoid prolonged sun exposure as photosensitivity reactions may occur.